FcRn inhibitors for myasthenia gravis

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of FcRn inhibitors for the maintenance treatment of myasthenia gravis in adult participants compared with control treatment (placebo, standard-of-care therapy, an alternative FcRn inhibitor, or an alternative immunomodulatory therapy). We will evaluate the efficacy of the treatment by the effect on disease severity and functional impairment, as assessed using a measurement tool validated for use in myasthenia gravis. Where possible, we will assess whether the effects of FcRn inhibitors differ according to different participant subgroups or different treatment regimens, or both. These data will be used to inform policymakers on the participant subgroups most likely to benefit from treatment and the most efficacious treatment regimen.

Authors

Institutions

Publication Details

Journal
Cochrane Database of Systematic Reviews
Published
2025-08-22
DOI
https://doi.org/10.1002/14651858.cd016097
Citations
2
Primary Topic
Myasthenia Gravis and Thymoma
Type
article
Field-Weighted Citation Impact
2.78
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

FcRn inhibitors for myasthenia gravis

James B Lilleker, Katherine Dodd, Jennifer Spillane, AM Forbes et al.
2 citations
Cochrane Database of Systematic Reviews
Myasthenia Gravis and Thymoma
2.78
article

FcRn inhibitors for myasthenia gravis

James B Lilleker, Katherine Dodd, Jennifer Spillane, AM Forbes, Jon Sussman, Fiona J. Clay, Ryan Keh, Laura M. White, Karen Storms
article en
2 citations

Abstract

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of FcRn inhibitors for the maintenance treatment of myasthenia gravis in adult participants compared with control treatment (placebo, standard-of-care therapy, an alternative FcRn inhibitor, or an alternative immunomodulatory therapy). We will evaluate the efficacy of the treatment by the effect on disease severity and functional impairment, as assessed using a measurement tool validated for use in myasthenia gravis. Where possible, we will assess whether the effects of FcRn inhibitors differ according to different participant subgroups or different treatment regimens, or both. These data will be used to inform policymakers on the participant subgroups most likely to benefit from treatment and the most efficacious treatment regimen.

Cochrane Database of Systematic ReviewsVol. 2025(8)
Lancashire Teaching Hospitals NHS Foundation Trust (GB), University of Tasmania (AU), University College London Hospitals NHS Foundation Trust (GB), University of Manchester (GB), Northern Health and Social Care Trust (GB), Victorian Institute of Forensic Medicine (AU), National Hospital for Neurology and Neurosurgery (GB), University College London (GB), Monash University (AU), Lancaster University (GB)
Zero hunger
Openalex Percentile: Top 9%
Myasthenia Gravis and Thymoma
2.78
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

FcRn inhibitors for myasthenia gravis — James B Lilleker, Katherine Dodd, et al. · Cochrane Database of Systematic Reviews (2025) | TGRS Research Map | TGRS